CRISPR Therapeutics AG (CRSP) Income Annual - Discounting Cash Flows
CRSP
CRISPR Therapeutics AG
CRSP (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
2015
12-31
2014
12-31
Report Filing 2025-05-06 2025-02-11 2024-02-21 2023-02-21 2022-02-15 2021-02-16 2020-02-12 2019-02-25 2018-03-08 2017-03-10 2015-12-31 2014-12-31
Revenue 36.98 35 371.2 0.436 913.1 0.543 289.6 3.12 41 5.16 0.247 0
Cost of Revenue 125.6 110.2 130.2 110.2 17.95 269.4 179.4 113.8 69.8 42.24 12.57 1.51
Gross Profit -88.65 -75.25 241 -109.8 895.1 -268.9 110.2 -110.6 -28.8 -37.07 -12.33 -1.51
Operating Expenses 385.7 391.3 463.5 563.3 521.6 85.57 63.49 48.29 35.84 31.06 13.4 5.11
Research & Development 307.3 320.7 387.3 461.6 438.6 266.9 179.4 113.8 69.8 42.24 12.57 1.51
Selling, General and Administrative 74.32 72.98 76.16 102.5 102.8 88.21 63.49 48.29 35.84 31.06 13.4 5.11
Other Operating Expenses 4.15 -2.31 0 -0.762 -19.84 -269.6 -179.4 -113.8 -69.8 -42.24 -12.57 -1.51
Operating Income -474.4 -466.6 -222.5 -673.2 373.5 -354.4 46.74 -158.9 -64.65 -68.13 -25.73 -6.63
Net Non-Operating Interest 0 0 0 0 0 0 10.03 0 0 -8.05 -0.108 0
Interest Income 0 0 0 0 0 0 10.03 0 0 0 0 0
Interest Expense 0 0 0 0 0 0 0 0 0 8.05 0.108 0
Equity & Other Income/(Expense) 92.72 103.9 71.82 22.66 6 6.38 10.53 -5.49 -1.96 53.46 0.016 -0.236
Income Before Tax -381.7 -362.7 -150.7 -650.5 379.5 -348.1 67.31 -164.4 -66.61 -22.72 -25.82 -6.86
Income Tax Expense 3.97 3.59 2.89 -0.325 1.87 0.809 0.448 0.553 1.75 0.484 0.007 -0.063
Income Attributable to Non-Controlling Interest 0 0 0 0 0 0 0 0 0 0 0 0
Net Income -385.7 -366.3 -153.6 -650.2 377.7 -348.9 66.86 -165 -68.36 -23.2 -25.83 -6.8
Depreciation and Amortization 19.22 19.26 19.84 24.17 17.95 9.18 4.72 3.52 3.02 1 0.127 0.038
EBITDA -455.2 -447.3 -202.7 -649 391.5 -345.3 51.47 -155.4 -61.62 -67.13 -25.6 -6.59
Earnings Per Share (EPS) -4.52 -4.34 -1.94 -8.36 4.97 -5.29 1.23 -3.44 -1.71 -1.89 -0.88 -0.23
Diluted Earnings Per Share -4.52 -4.34 -1.94 -8.36 4.7 -5.29 1.17 -3.44 -1.71 -1.89 -0.88 -0.23
Weighted Average Shares Outstanding 85.94 84.36 79.22 77.75 75.95 65.95 54.39 47.96 39.97 12.26 29.3 29.3
Diluted Weighted Average Shares Outstanding 85.94 84.36 79.22 77.75 80.39 65.95 56.93 47.96 40.06 12.26 29.3 29.3
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us